Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies
Can-Fite BioPharma (NYSE American: CANF) announced the successful completion of pre-clinical studies showing that its CBD-rich T3/C15 cannabis fraction has an inhibitory effect on liver fibrosis. This condition, associated with severe liver diseases like NAFLD and HCC, involves the excessive buildup of scar tissue in the liver. The studies revealed that the therapeutic effects are mediated through the A3 adenosine receptor (A3AR). Can-Fite's drug candidate Namodenoson is progressing to pivotal Phase III trials for liver cancer and Phase IIb for NASH, with patent applications filed for cannabinoid-based therapies.
- Successful pre-clinical studies on CBD-rich T3/C15 cannabis fraction demonstrating inhibition of liver fibrosis.
- Therapeutic effects mediated via A3 adenosine receptor (A3AR), indicating a targeted approach.
- Namodenoson advancing to Phase III trials for liver cancer and Phase IIb for NASH, showing strong pipeline development.
- Recent patent applications protect cannabinoid-based treatments, enhancing competitive positioning.
- None.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today it has completed a set of pre-clinical studies demonstrating that CBD rich T3/C15 cannabis fraction induces an inhibitory effect on liver fibrosis. Fibrosis of the liver occurs when injured or inflamed liver cells can no longer repair themselves, resulting in an abnormally large amount of scar tissue. Liver fibrosis is associated with increased liver disease including nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
As a global leader in discovering and developing drugs which target the A3 adenosine receptor (A3AR), Can-Fite showed that cannabis derived compounds bind to A3AR, mediating therapeutic effects. CBD rich T3/C15 cannabis fraction inhibited the proliferation of LX-2 hepatic-stellate cells, the liver cell type mediating the development of fibrosis. This inhibitory response was neutralized by an antagonist to the A3AR, demonstrating that the anti-fibrotic effect was mediated via the A3AR.
“These data together with our unparalleled expertise in the development of liver fatty disease therapeutics that target A3AR, enable Can-Fite to contribute to unlocking the vast potential of cannabis derived compounds for the effective treatment of this pathological condition,” stated Can-Fite CEO Dr. Pnina Fishman.
Can-Fite’s small molecule drug candidate Namodenoson has shown efficacy in liver diseases and is headed into a pivotal Phase III in liver cancer and a Phase IIb in NASH. The Company has filed patent applications protecting its discovery of cannabinoid-based treatments where A3AR is overexpressed including liver cancer, other cancers, autoimmune, inflammatory, and metabolic diseases.
According to Adroit Market Research, the medical cannabis market is projected to grow at a CAGR of
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the recent outbreak of coronavirus; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005188/en/
FAQ
What did Can-Fite BioPharma announce regarding liver fibrosis on [date]?
How does the CBD-rich T3/C15 cannabis fraction work against liver fibrosis?
What are the next steps for Can-Fite's drug candidate Namodenoson?
What market potential does the medical cannabis sector have according to Can-Fite?
What regulatory designations has Namodenoson received?
